UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of ~~January~~February 2023

Commission File Number: 001-40106

4D pharma plc

(Translation of Registrant’s name into English)

5th Floor, 9 Bond Court

Leeds

LS1 2JZ

United Kingdom

Tel: +44 (0) 113 895 013

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

On ~~December~~February 302, ~~2022~~2023, 4D pharma plc (the “Company,” “4D,” “4D pharma,” “we,” “us” or “our”) issued a press release entitled “4D pharma Announces anUpdated ~~Update~~Results onfrom ~~Administration~~the ~~and~~Renal ~~Suspension~~Cell ofCarcinoma ~~Trading”~~Cohort ~~regarding~~of athe ~~circular~~Phase ~~being~~I/II ~~posted~~Study toof the ~~Company’s~~Combination ~~shareholders~~of onMRx0518 ~~December~~and ~~30,~~KEYTRUDA® ~~2022,~~(pembrolizumab)” ~~which~~regarding ~~contains~~updated aclinical ~~notice~~data from Part B of aits ~~General~~signal ~~Meeting~~finding study of MRx0518 in combination with Merck & Co, Inc.’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) toin bepatients ~~held~~with solid tumors that have progressed on ~~January~~a ~~16,~~prior ~~2023~~immune checkpoint inhibitor.

A copy of the press release ~~and~~is ~~a copy of the circular are~~ attached as Exhibit 99.1 ~~and Exhibit 99.2, respectively,~~ to this current report on Form 6-K and ~~are~~is incorporated by reference herein. This press release ~~and~~is ~~circular are each~~ incorporated by reference into the registration statements on Form F-3 (File No. 333-263372 and File No. 333-264419) of 4D pharma plc, filed with the U.S. Securities and Exchange Commission, to be a part thereof from the date on which this press release is ~~and circular are~~ submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

INDEX TO EXHIBITS

Exhibit
Number		Exhibit Title
99.1		Press Release, dated ~~December~~February 302, ~~2022~~2023.
99.2		Notice of General Meeting of Shareholders Circular, dated December 30, 2022.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	4D pharma plc
Date: January 3, 2023	/s/ James Clark
Date: February 7, 2023	/s/ James Clark
	James Clark
	Administrator

Filing Compare · 4D Pharma PLC